Intellia Therapeutics (NTLA) Leases (2019 - 2025)
Intellia Therapeutics (NTLA) has disclosed Leases for 7 consecutive years, with $106.0 million as the latest value for Q4 2025.
- Quarterly Leases fell 51.68% to $106.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.0 million through Dec 2025, down 51.68% year-over-year, with the annual reading at $106.0 million for FY2025, 51.68% down from the prior year.
- Leases for Q4 2025 was $106.0 million at Intellia Therapeutics, down from $117.9 million in the prior quarter.
- The five-year high for Leases was $219.3 million in Q4 2024, with the low at $1.4 million in Q2 2021.
- Average Leases over 5 years is $101.1 million, with a median of $108.2 million recorded in 2024.
- The sharpest move saw Leases tumbled 94.03% in 2021, then skyrocketed 5169.64% in 2022.
- Over 5 years, Leases stood at $79.1 million in 2021, then skyrocketed by 68.15% to $133.1 million in 2022, then fell by 13.3% to $115.4 million in 2023, then skyrocketed by 90.07% to $219.3 million in 2024, then plummeted by 51.68% to $106.0 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $106.0 million, $117.9 million, and $129.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.